Remedies for vesical stimulation association with prostatauxe

A therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (Ia):

• [wherein R1 and X1—X2—X3 have the same significances as
• 11 defined above, respectively;
• Ya represents —CH2SO2—, —SCH2—, —SOCH2—, —SO2CH2— or —OCH2—;
• and
• when Ya is —CH2SO2—, —SCH2—, —SOCH2— or —SO2CH2—, R2a represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, trifluoromethyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group or formula (II):
• 12
• (wherein n is 0 or 1;
• R3 and R4, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or trifluoromethyl, or R3 and R4 may be combined together with the adjacent carbon atom to form cycloalkyl;
• and Q represents hydroxy, substituted or unsubstituted lower alkoxy, amino or halogen), and when Ya is —OCH2—,
• R2a represents a hydrogen atom, substituted or unsubstituted lower alkenyl, trifluoromethyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group or formula (II):
• 13
• (wherein n, R3, R4 and Q have the same significances as defined above, respectively)] or a pharmaceutically acceptable salt thereof.

A therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (Ib):

• 16
• [wherein R1 and X1—X2—X3 have the same significances as defined above, respectively;
• Yb represents —CH2O—, —CH2S—, —CH2SO—, —CH═CH— or —(CH2)p—
• (wherein p has the same significance as defined above);
• and R2b represents formula (III):
• 17
• or a pharmaceutically acceptable salt thereof.